MINNEAPOLIS, Nov 02, 2011 (BUSINESS WIRE) --
To address surgeon needs of rapidly managing hemostasis in minimally invasive spine surgery, Medtronic, Inc. (NYSE: MDT) announced today the launch of the Aquamantys(R) Mini EVS 3.4 Epidural Vein Sealer. This latest addition to the spine portfolio of the Advanced Energy business of Medtronic delivers proprietary Transcollation(R) technology, a combination of RF energy and saline that has been shown to reduce blood loss during spine surgery.
The Mini EVS 3.4 Epidural Vein Sealer is designed to optimize visibility and control epidural bleeding by enabling prophylactic compression and treatment of epidural veins before they begin to bleed. Its insulated shaft enables simultaneous retraction and electrode use near sensitive tissue such as dura and nerve roots. The 3.4 mm tip size allows for use in procedures with small epidural access points.
"The Mini EVS 3.4 will give me the ability to deliver Transcollation technology through even smaller anatomical access points than I'm capable of now," said Dr. Paul Santiago, a neurosurgeon at Washington University School of Medicine. "This will be extremely helpful in controlling epidural bleeding before it becomes a problem, and the small size of the device will also allow me to maintain visibility around critical structures such as dura and nerve roots."
"Developed in direct response to surgeon feedback, the Mini EVS 3.4 is the latest addition to a growing Transcollation spine portfolio and will give surgeons greater choice and flexibility as they strive to prevent and treat intra-operative blood loss," said Mark Fletcher, president of the Surgical Technologies business at Medtronic. "We are very excited about this as well as other products in our pipeline to address surgeon needs in spine surgery."
About Medtronic
Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology - alleviating pain, restoring health and extending life for millions of people around the world.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
SOURCE: Medtronic, Inc.
Medtronic, Inc. Cindy Resman, 763-505-0291 Public Relations or Jeff Warren, 763-505-2696 Investor Relations